Stories about pain

Subscribe to pain

06.10.2020 – 14:00

Merck KGaA
Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis

Darmstadt, Germany (ots/PRNewswire) - - Merck out-licenses promising clinical-stage program to Novartis - Anti-ADAMTS5 Nanobody® programis Phase II-ready with novel MoA which could protect against cartilage damage and reduce joint pain - Merck receives upfront payment of EUR 50 million with the potential of ...

more
29.09.2020 – 09:30

Medasense Biometrics Ltd
New Study: Postoperative Pain Can Be Reduced by Using NOL Monitoring to Guide Analgesic Medication During Surgery

Ramat Gan, Israel (ots/PRNewswire) - A new study has found that monitoring pain response levels during surgery with NOL technology (Medasense, Ramat Gan, Israel) can help reduce postoperative pain. Exploring the potential use of NOL monitoring to help enhance recovery after surgery, the study demonstrated that ...

more
21.07.2020 – 16:00

Grünenthal Group
Grünenthal and Averitas Pharma Announce U.S. FDA Approval of QUTENZA® for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy of the Feet

Aachen, Germany & Morristown, N.J. (ots) - - Neuropathic pain associated with diabetic peripheral neuropathy is a progressive and debilitating complication of diabetes that will affect approximately more than 5 million Americans in 20201. - QUTENZA® is the first and only topical, non-systemic, non-opioid pain ...

more
04.06.2020 – 14:16

Synformulas GmbH

2
Innovation: Intelligent bacteria demonstrate high efficacy in the treatment of widespread disease irritable bowel syndrome with typical symptoms of recurrent diarrhoea, abdominal pain, bloating and constipation

more
09.03.2020 – 18:01

Senzer Limited
Senzer Secures US Clinical Data Package for the Treatment of Chemotherapy Induced Adverse Events

London (ots/PRNewswire) - Senzer has secured the Investigational New Drug application and data package for its ongoing FDA registration programme from its former US strategic partner and will now push ahead to get its cannabinoid respiratory device approved for treating side effects induced by anti-cancer treatments ...

more
29.01.2020 – 10:27

Grünenthal Group
Grünenthal expands its network through Innovation Hub in Boston

Aachen, Germany and Boston, USA (ots) - Grünenthal announced today that it has officially inaugurated its Innovation Hub in Boston, Massachusetts to strengthen and expand its network with leading scientists and institutions. With its Innovation Hubs, Grünenthal strives to establish centres of excellence for pain research, aiming to identify and develop promising external innovation opportunities in the therapeutic area ...

more
10.09.2019 – 09:40

Grünenthal Group
Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain

Aachen, Germany, and Melbourne, Australia (ots) - Grünenthal, a global leader in pain management, and Mesoblast Limited (ASX: MSB; Nasdaq: MESO), a world leader in allogeneic cellular medicines for inflammatory diseases, today announced that they have entered into a strategic partnership to develop and ...

more
02.05.2019 – 14:00

Grünenthal Group
Five young scientists win EFIC-Grünenthal Grant 2018

Brussels/Aachen (ots) - - Five creative ideas aimed at advancing research in pain have been selected to receive funding from the prestigious EFIC-Grünenthal Grant (E-G-G) 2018. - The selected teams of young scientists will start executing there innovative projects with the ambitious objective to improve the lives of people in pain. The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have ...

more
05.11.2018 – 12:10

Grünenthal Group
Grünenthal acquires global rights for Qutenza®

Aachen (ots) - Grünenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for the dermal pain patch Qutenza® (8% capsaicin) from Acorda Therapeutics, Inc (USA). Grünenthal is now the sole owner of Qutenza® worldwide, including the US, Latin America, Asia and Australia. Grünenthal had already acquired exclusive commercial rights for ...

more
30.10.2018 – 08:43

Grünenthal Group
Grünenthal agrees US$ 922 m deal with AstraZeneca for Nexium and Vimovo

Aachen (ots) - - Biggest single investment in Grünenthal's history that will significantly strengthen the company's leading position in pain management - Gastroprotective therapies to address a high unmet medical need [1] in pain patients on non-steroidal anti-inflammatory drugs (NSAIDs) Grünenthal today announced that it has agreed to acquire AstraZeneca's European ...

more

1